The DOI matches its Crossref record.
First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors
Open accessAbstract
// C. Willemien Menke-van der Houven van Oordt 1 , Carlos Gomez-Roca 2 , Carla van Herpen 3 , Andrew L. Coveler 4 , Devalingam Mahalingam 5 , Henk M. W. Verheul 1 , Winette T. A. van der Graaf 3 , Randolph Christen 6 , Dominik Rüttinger 7 , Stefan Weigand 7 , Michael A. Cannarile 7 , Florian Heil 7 , Michael Brewster 8 , Antje-Christine Walz 9 , Tapan K. Nayak 9 , Ernesto Guarin 9 , Valerie Meresse 9 and Christophe Le Tourneau 10 1 Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands 2 Clinical Research Unit, Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse – Oncopole, Toulouse, France 3 Radboud University Medical Center, Nijmegen, The Netherlands 4 Department of Medicine, Division of Oncology, University of Washington, Seattle, WA, USA 5 Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, TX, USA 6 Product Development, Safety Risk Management, Roche, Basel, Switzerland 7 Pharma Research & Early Development, Roche Innovation Center, Penzberg, Germany 8 Pharma Research & Early Development, Roche Innovation Centre, Welwyn, UK 9 Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland 10 Department of Medical Oncology, Institut Curie, Saint-Cloud & Paris, France, and Versailles-Saint-Quentin-en-Yvelines University, Versailles, France Correspondence to: C. Willemien Menke-van der Houven van Oordt, email: // Keywords : RG7356, anti-CD44 humanized antibody, advanced solid tumors, advanced CD44-expressing solid malignancies, phase I trial Received : March 28, 2016 Accepted : July 10, 2016 Published : August 05, 2016 Abstract Transmembrane glycoprotein CD44 is overexpressed in various malignancies. Interactions between CD44 and hyaluronic acid are associated with poor prognosis, making CD44 an attractive therapeutic target. We report results from a first-in-human phase I trial of RG7356, a recombinant anti-CD44 immunoglobulin G1 humanized monoclonal antibody, in patients with advanced CD44-expressing solid malignancies. Sixty-five heavily pretreated patients not amenable to standard therapy were enrolled and received RG7356 intravenously biweekly (q2w) or weekly (qw) in escalating doses from 100 mg to 2,250 mg. RG7356 was well tolerated. Most frequent adverse events were fever, headache and fatigue. Dose-limiting toxicities included headache (1,500 mg q2w and 1,350 mg qw) and febrile neutropenia (2,250 mg q2w). The maximum tolerated dose with q2w dosing was 1,500 mg, but was not defined for qw dosing due to early study termination. Clinical efficacy was modest; 13/61 patients (21%) experienced disease stabilization lasting a median of 12 (range, 6–35) weeks. No apparent dose- or dose schedule-dependent changes in biological activity were reported from blood or tissue analyses. Tumor-targeting by positron emission tomography (PET) using 89 Zr-labeled RG7356 was observed for doses ≥200 mg (q2w) warranting further investigation of this agent in combination regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007
Clara, J. A., Monge, C., Yang, Y., & Takebe, N. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0293-2 · Cited by 752
Cancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 553
ImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
A druggable copper-signalling pathway that drives inflammation
Solier, S., Müller, S., Cañeque, T., Versini, A., Mansart, A., Sindikubwabo, F., Baron, L., Emam, L., Gestraud, P., Pantoș, G. D., et al. (2023) · Nature · doi:10.1038/s41586-023-06017-4 · Cited by 330
Metadata
- Authors
- Menke-van der Houven van Oordt, C. W., Gomez-Roca, C., van Herpen, C., Coveler, A. L., Mahalingam, D., Verheul, H. M. W., van der Graaf, W. T. A., Christen, R., Rüttinger, D., Weigand, S., Cannarile, M. A., Heil, F., Brewster, M., Walz, A.-C., Nayak, T. K., Guarin, E., Meresse, V., & Le Tourneau, C.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-08-05
- Volume
- 7
- Issue
- 48
- Pages
- 80046-80058
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2486571534
- Cited by
- 158
- References
- 0
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors. https://app.cochat.ai/papers/10.18632/oncotarget.11098
- The paper
- Menke-van der Houven van Oordt, C. W., Gomez-Roca, C., van Herpen, C., Coveler, A. L., Mahalingam, D., Verheul, H. M. W., van der Graaf, W. T. A., Christen, R., Rüttinger, D., Weigand, S., Cannarile, M. A., Heil, F., Brewster, M., Walz, A.-C., Nayak, T. K., Guarin, E., Meresse, V., & Le Tourneau, C. (2016). First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors. Oncotarget. https://doi.org/10.18632/oncotarget.11098
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.